Forbes, Oct. 13, 2006http://www.forbes.com/forbeslife/health/feeds/hscout/2006/10/12/hscout535432.html A new class of diabetes drugs appears to hold promise against sepsis, Texas researchers report. In animal studies, giving a compound from the family of aldose reductase inhibitors stopped the deadly inflammation of sepsis, which is caused by the overreaction of the immune system to a bacterial infection, according to a report in the Oct. 9 online issue of Circulation. Study author is Satish Srivastava, a professor of biochemistry and molecular biology at the University of Texas Medical School Branch at Galveston. Sepsis killed more than 120,000 hospitalized people in the United States in 2000, and the incidence has been increasing -- from 82.7 cases per 100,000 Americans in 1979 to 240.4 per 100,000 in 2000. "It affects the lungs and kidneys, but the major cause of death in sepsis patients is cardiovascular collapse," Srivastava said. (This news story continues to run widely throughout the U.S. and internationally. Today it appears in an additional 7 publications.)